Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...
A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...
The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for ...
Intellia Therapeutics’ CRISPR-based therapy lonvoguran ziclumeran reduced hereditary angioedema attacks by 87% in a pivotal ...
Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...
CRSP eyes a Q1 beat as rising Casgevy uptake, improving sales outlook and a strong Earnings ESP set the stage ahead of results.
We'll know more about the company's medium-term prospects by the end of the year.
Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...
There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...
View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results